Chromogranin A as serum marker for gastroenteropancreatic neuroendocrine tumors: A single center experience and literature review

Cancers

Volumn 4, Issue 1, 2012, Pages 141-155

  Nölting, Svenja ^a   Kuttner, Axel ^a   Lauseker, Michael ^b   Vogeser, Michael ^a   Haug, Alexander ^a   Herrmann, Karin A ^a   Hoffmann, Johannes N ^b   Spitzweg, Christine ^a   Göke, Burkhard ^a   Auernhammer, Christoph J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alkaline phosphatase; Chromogranin A; CIS bio assay; Gastroenteropancreatic system; Liver metastases; Neuroendocrine tumors; Sensitivity; Urinary 5 hydroxyindoleacetic acid

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALKALINE PHOSPHATASE; CHROMOGRANIN A;

5 HYDROXYINDOLEACETIC ACID URINE LEVEL; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; CHROMOGRANIN A BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; IMMUNORADIOMETRIC ASSAY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDGUT; MIDGUT NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PERITONEUM METASTASIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINE LEVEL;

EID: 84859041905     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4010141     Document Type: Article

References (33)

1. Modlin, I.M.; Gustafsson, B.I.; Moss, S.F.; Pavel, M.; Tsolakis, A.V.; Kidd, M. Chromogranin A-Biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 2010, 17, 2427-2443.
2. Deftos, L.J. Chromogranin A: Its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr. Rev. 1991, 12, 181-187.
3. Taupenot, L.; Harper, K.L.; O'Connor, D.T. The chromogranin-secretogranin family. N. Engl. J. Med. 2003, 348, 1134-1149.
4. Nobels, F.R.; Kwekkeboom, D.J.; Bouillon, R.; Lamberts, S.W. Chromogranin A: Its clinical value as marker of neuroendocrine tumours. Eur. J. Clin. Invest. 1998, 28, 431-440.
5. Nobels, F.R.; Kwekkeboom, D.J.; Coopmans, W.; Schoenmakers, C.H.; Lindemans, J.; de Herder, W.W.; Krenning, E.P.; Bouillon, R.; Lamberts, S.W. Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J. Clin. Endocrinol. Metab. 1997, 82, 2622-2628.
6. O'Connor, D.T.; Deftos, L.J. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N. Engl. J. Med. 1986, 314, 1145-1151.
7. Sobol, R.E.; Memoli, V.; Deftos, L.J. Hormone-negative, chromogranin A-positive endocrine tumors. N. Engl. J. Med. 1989, 320, 444-447.
8. Eriksson, B.; Oberg, K.; Stridsberg, M. Tumor markers in neuroendocrine tumors. Digestion 2000, 62, S33-S38.
9. Oberg, K. The ultimate biochemical diagnosis of gastro-enteropancreatic tumours. Digestion 1996, 57, S45-S47.
10. Ahmed, A.; Turner, G.; King, B.; Jones, L.; Culliford, D.; McCance, D.; Ardill, J.; Johnston, B.T.; Poston, G.; Rees, M., et al. Midgut neuroendocrine tumours with liver metastases: Results of the UKINETS study. Endocr. Relat. Cancer 2009, 16, 885-894.
11. O'Toole, D.; Grossman, A.; Gross, D.; Delle Fave, G.; Barkmanova, J.; O'Connor, J.; Pape, U.F.; Plockinger, U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Biochemical markers. Neuroendocrinology 2009, 90, 194-202.
12. Vinik, A.I.; Woltering, E.A.; Warner, R.R.; Caplin, M.; O'Dorisio, T.M.; Wiseman, G.A.; Coppola, D.; Go, V.L. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010, 39, 713-734.
13. Lawrence, B.; Gustafsson, B.I.; Kidd, M.; Pavel, M.; Svejda, B.; Modlin, I.M. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 2011, 40, 111-134.
14. Ferrari, L.; Seregni, E.; Lucignani, G.; Bajetta, E.; Martinetti, A.; Aliberti, G.; Pallotti, F.; Procopio, G.; Della Torre, S.; Luksch, R., et al. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int. J. Biol. Markers 2004, 19, 295-304.
15. Stridsberg, M.; Eriksson, B.; Oberg, K.; Janson, E.T. A comparison between three commercial kits for chromogranin A measurements. J. Endocrinol. 2003, 177, 337-341.
16. Zatelli, M.C.; Torta, M.; Leon, A.; Ambrosio, M.R.; Gion, M.; Tomassetti, P.; de Braud, F.; Delle Fave, G.; Dogliotti, L.; degli Uberti, E.C. Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study. Endocr. Relat. Cancer 2007, 14, 473-482.
17. Baudin, E.; Bidart, J.M.; Bachelot, A.; Ducreux, M.; Elias, D.; Ruffie, P.; Schlumberger, M. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann. Oncol. 2001, 12, S79-S82.
18. Schurmann, G.; Raeth, U.; Wiedenmann, B.; Buhr, H.; Herfarth, C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J. Surg. 1992, 16, 697-701.
19. Nikou, G.C.; Marinou, K.; Thomakos, P.; Papageorgiou, D.; Sanzanidis, V.; Nikolaou, P.; Kosmidis, C.; Moulakakis, A.; Mallas, E. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 2008, 8, 510-519.
20. Tomassetti, P.; Migliori, M.; Simoni, P.; Casadei, R.; de Iasio, R.; Corinaldesi, R.; Gullo, L. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur. J. Gastroenterol. Hepatol. 2001, 13, 55-58.
21. Arnold, R.; Wilke, A.; Rinke, A.; Mayer, C.; Kann, P.H.; Klose, K.J.; Scherag, A.; Hahmann, M.; Muller, H.H.; Barth, P. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin. Gastroenterol. Hepatol. 2008, 6, 820-827.
22. Janson, E.T.; Holmberg, L.; Stridsberg, M.; Eriksson, B.; Theodorsson, E.; Wilander, E.; Oberg, K. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. 1997, 8, 685-690.
23. Kolby, L.; Bernhardt, P.; Sward, C.; Johanson, V.; Ahlman, H.; Forssell-Aronsson, E.; Stridsberg, M.; Wangberg, B.; Nilsson, O. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul. Pept. 2004, 120, 269-273.
24. Korse, C.M.; Bonfrer, J.M.; Aaronson, N.K.; Hart, A.A.; Taal, B.G. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 2009, 89, 296-301.
25. Clancy, T.E.; Sengupta, T.P.; Paulus, J.; Ahmed, F.; Duh, M.S.; Kulke, M.H. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig. Dis. Sci. 2006, 51, 877-884.
26. Campana, D.; Nori, F.; Piscitelli, L.; Morselli-Labate, A.M.; Pezzilli, R.; Corinaldesi, R.; Tomassetti, P. Chromogranin A: Is it a useful marker of neuroendocrine tumors? J. Clin. Oncol. 2007, 25, 1967-1973.
27. Nehar, D.; Lombard-Bohas, C.; Olivieri, S.; Claustrat, B.; Chayvialle, J.A.; Penes, M.C.; Sassolas, G.; Borson-Chazot, F. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin. Endocrinol. (Oxf.) 2004, 60, 644-652.
28. Walter, T.; Chardon, L.; Chopin-Laly, X.; Raverot, V.; Caffin, A.G.; Chayvialle, J.A.; Scoazec, J.Y.; Lombard-Bohas, C. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur. J. Cancer 2011, in press.
29. Pirker, R.A.; Pont, J.; Pohnl, R.; Schutz, W.; Griesmacher, A.; Muller, M.M. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin. Chem. Lab. Med. 1998, 36, 837-840.
30. Welin, S.; Stridsberg, M.; Cunningham, J.; Granberg, D.; Skogseid, B.; Oberg, K.; Eriksson, B.; Janson, E.T. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009, 89, 302-307.
31. Yao, J.C.; Pavel, M.; Phan, A.T.; Kulke, M.H.; Hoosen, S.; St. Peter, J.; Cherfi, A.; Oberg, K.E. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J. Clin. Endocrinol. Metab. 2011, 96, 3741-3749.
32. Vezzosi, D.; Walter, T.; Laplanche, A.; Raoul, J.L.; Dromain, C.; Ruszniewski, P.; d'Herbomez, M.; Guigay, J.; Mitry, E.; Cadiot, G., et al. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: Screening for false positives and a prospective follow-up study. Int. J. Biol. Markers 2011, 26, 94-101.
33. Bland, J.M.; Altman, D.G. Calculating correlation coefficients with repeated observations: Part 1-Correlation within subjects. BMJ 1995, 310, 446.